The GSK case was swiftly dealt with. However, the industry cannot yet relax, says ABPI president and Sanofi-Aventis UK managing
director Nigel Brooksby. "We have raised the profile, but we now need a sustained effort," he says. "We need a safe environment,
free of violence....The dream is that one day we won't have to use animals—but that is still a dream. We need to sustain this
momentum: We are at the beginning [of the fight against extremists], not the end."
Sarah Houlton is Pharmaceutical Executive's global correspondent. She can be reached at firstname.lastname@example.org